High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatinib 400 mg twice a day as initial...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2009-10, Vol.27 (28), p.4754-4759
Hauptverfasser:	CORTES, Jorge E, KANTARJIAN, Hagop M, SALVADO, August, MCDOUGALL, Karen, ALBITAR, Maher, RADICH, Jerald, GOLDBERG, Stuart L, POWELL, Bayard L, GILES, Francis J, WETZLER, Meir, AKARD, Luke, BURKE, John M, KERR, Robert, SALEH, Mansoor
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Diarrhea - chemically induced Dose-Response Relationship, Drug Drug Administration Schedule Fatigue - chemically induced Female Fusion Proteins, bcr-abl - genetics Hematologic and hematopoietic diseases Humans Imatinib Mesylate In Situ Hybridization, Fluorescence Kaplan-Meier Estimate Karyotyping Leukemia, Myeloid, Chronic-Phase - diagnosis Leukemia, Myeloid, Chronic-Phase - drug therapy Leukemia, Myeloid, Chronic-Phase - genetics Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Nausea - chemically induced ORIGINAL REPORTS Piperazines - administration & dosage Piperazines - adverse effects Piperazines - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Time Factors Treatment Outcome Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!